SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.
Amdal CD, Falk RS, Alanya A, Schlichting M, Roychoudhury S, Bhatnagar V, Wintner LM, Regnault A, Ingelgård A, Coens C, le Cessie S, Holzner B, Chang J, Taphoorn M, Cislo P, Giesinger JM, Cappelleri JC, Pawar V, Ten Seldam S, Papadopoulos EJ, Calvert MJ, Joseph KL, Bottomley A, Griebsch I, Arraras JI, Astrup GL, Basch E, Belančić A, Brundage M, Campbell A, Rerhou Rantell K, Cocks K, Cherny N, Eremenco S, Ferrer M, Fiero MH, Gerlinger C, Goetghebeur E, Grouven U, Lauer A, Aiyegbusi OL, Machingura A, Mizusawa J, Molenberghs G, Aa Petersen M, Reijneveld JC, Ringash J, Rumpold G, Rutherford C, Quinten C, Sail K, Sasseville M, Sauerbrei W, Schiel A, Smith AW, Snyder C, Velikova G, Wang XS, Bjordal K, Pe M; SISAQOL-IMI Consortium.
Amdal CD, et al.
Lancet Oncol. 2025 Dec;26(12):e683-e693. doi: 10.1016/S1470-2045(25)00520-0.
Lancet Oncol. 2025.
PMID: 41308689
Review.